Journal
JOURNAL OF LIPID RESEARCH
Volume 62, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jlr.2021.100026
Keywords
Cancer; Cholesterol; Membranes/Fluidity; Omega-3 fatty acids; Receptors/Plasma membrane; Super-resolution microscopy
Categories
Funding
- Texas A&M University Regulatory Science in Environmental Health and Toxicology Training Grant [T32-ES026568]
- PhRMA Foundation
- National Science Foundation REU Site Summer Undergraduate Research Program in Biochemistry [NSF DBI-1358941]
Ask authors/readers for more resources
The study identified that docosahexaenoic acid (DHA) reduces EGFR signaling by reshaping EGFR proteolipid nanodomains, suggesting the potential of using membrane therapy to target plasma membrane organization and reduce cancer risk.
Epidermal growth factor receptor (EGFR) signaling drives the formation of many types of cancer, including colon cancer. Docosahexaenoic acid (DHA, 22:6(Delta 4,7)(,1)(0,13,16,19)) a chemoprotective long-chain n-3 polyunsaturated fatty acid suppresses EGFR signaling. However, the mechanism underlying this phenotype remains unclear. Therefore, we used superresolution microscopy techniques to investigate the mechanistic link between EGFR function and DHA-induced alterations to plasma membrane nanodomains. Using isogenic in vitro (YAMC and IMCE mouse colonic cell lines) and in vivo (Drosophila, wild type and Fat-1 mice) models, cellular DHA enrichment via therapeutic nanoparticle delivery, endogenous synthesis, or dietary supplementation reduced EGFR-mediated cell proliferation and downstream Ras/ERK signaling. Phospholipid incorporation of DHA reduced membrane rigidity and the size of EGFR nanoclusters. Similarly, pharmacological reduction of plasma membrane phosphatidic acid (PA), phosphatidylinositol-4,5-bisphosphate (PIP2) or cholesterol was associated with a decrease in EGFR nanocluster size. Furthermore, in DHA-treated cells only the addition of cholesterol, unlike PA or PIP2, restored EGFR nanoscale clustering. These findings reveal that DHA reduces EGFR signaling in part by reshaping EGFR proteolipid nanodomains, supporting the feasibility of using membrane therapy, i.e., dietary/drug-related strategies to target plasma membrane organization, to reduce EGFR signaling and cancer risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available